摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Benzyloxyphenyl)-4-hydroxymethyl-2-pyrrolidone | 73422-75-0

中文名称
——
中文别名
——
英文名称
1-(4-Benzyloxyphenyl)-4-hydroxymethyl-2-pyrrolidone
英文别名
(RS)-1-(4-Benzyloxy-phenyl)-4-hydroxymethyl-pyrrolidin-2-one;4-(hydroxymethyl)-1-(4-phenylmethoxyphenyl)pyrrolidin-2-one
1-(4-Benzyloxyphenyl)-4-hydroxymethyl-2-pyrrolidone化学式
CAS
73422-75-0
化学式
C18H19NO3
mdl
——
分子量
297.354
InChiKey
XCPPOMFQMGXNTO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    564.4±30.0 °C(Predicted)
  • 密度:
    1.219±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:66f6a5a574d339976ca317f003860c07
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(4-Benzyloxyphenyl)-4-hydroxymethyl-2-pyrrolidone 在 palladium on activated charcoal 氢气potassium carbonate三乙胺 作用下, 以 甲醇二氯甲烷氯仿N,N-二甲基甲酰胺 为溶剂, 25.0~80.0 ℃ 、101.33 kPa 条件下, 反应 22.0h, 生成 methyl 4-<1-(4-hydroxyphenyl)-2-oxo-pyrrolidin-4-yl>-methyloxybenzoate
    参考文献:
    名称:
    Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses
    摘要:
    The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.
    DOI:
    10.1016/0223-5234(94)90029-9
  • 作为产物:
    参考文献:
    名称:
    Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses
    摘要:
    The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.
    DOI:
    10.1016/0223-5234(94)90029-9
点击查看最新优质反应信息

文献信息

  • 4-pyrrolidino-phenyl-benzyl ether derivatives
    申请人:Iding Hans
    公开号:US20060122235A1
    公开(公告)日:2006-06-08
    The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.
    本发明涉及外消旋或对映纯的4-吡咯烷基衍生物,其制备方法,包含该衍生物的制药组合物,以及其在预防和治疗疾病中的应用,特别是在通过单胺氧化酶B抑制剂介导的疾病中,特别是阿尔茨海默病或老年性痴呆症的应用。
  • 4-Pyrrolidino-phenyl-benzyl ether derivatives
    申请人:——
    公开号:US20040106650A1
    公开(公告)日:2004-06-03
    The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.
    本发明涉及外消旋或对映纯的4-吡咯烷基衍生物,其制备方法,包含该衍生物的制药组合物,以及它们在预防和治疗疾病方面的应用,特别是通过单胺氧化酶B抑制剂介导的疾病,特别是阿尔茨海默病或老年性痴呆症。
  • Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS
    申请人:TAIHO PHARMACEUTICAL COMPANY, LIMITED
    公开号:EP1000620A1
    公开(公告)日:2000-05-17
    Lp(a)-lowering agents or apo(a) production inhibitors containing as the active ingredient phenylcarboxylic acid derivatives represented by general formula (1) or salts thereof, wherein R1 represents optionally substituted phenyl; A represents lower alkylene or lower alkyleneoxy; B represents methylene or carbonyl; D represents lower alkylene; E represents lower alkylene or lower alkenylene; R2 represents hydrogen or lower alkyl; and l, m and n are each 0 or 1. These drugs can significantly lower Lp(a) while scarcely showing any side effects.
    Lp(a)降低剂或apo(a)生成抑制剂,其活性成分为通式(1)代表的苯基羧酸衍生物或其盐类,其中R1代表任选取代的苯基;A代表低级亚烷基或低级亚烷氧基;B代表亚甲基或羰基;D代表低级亚烷基;E代表低级亚烷基或低级亚烯基;R2代表氢或低级亚烷基;l、m和n均为0或1。这些药物可以大大降低脂蛋白(a),同时几乎没有任何副作用。
  • Phenylcarboxylic acid derivatives having a hetero ring
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP0393607B1
    公开(公告)日:1996-02-21
  • ANCHER, J. -F.;BOURGERY, G.;DOSTERT, P.;DOUZON, C.;GUERRET, P.;LACOUR, A.+
    作者:ANCHER, J. -F.、BOURGERY, G.、DOSTERT, P.、DOUZON, C.、GUERRET, P.、LACOUR, A.+
    DOI:——
    日期:——
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦